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Summary
BACKGROUND: Psychotropic medication is commonly
used in nursing homes, to treat behavioural and psycholo-
gical symptoms of dementia (BPSD) for example. Treat-
ment with antipsychotics may improve BPSD in some res-
idents but can be associated with serious side effects, such
as higher mortality, faster disease progression and
cerebrovascular events. In the current study, psychotropic
medication use was analysed in a representative sample
of nursing home residents in the German-speaking part of
Switzerland, at entry and during follow-up.
METHODS: Retrospective analysis of the Resident
Assessment Instrument Minimum Data Set (RAI-MDS) of
90 nursing homes at entry (n = 18853) and during follow-
up (n = 12101).
RESULTS: At entry, 7580 residents (40.2%) were dia-
gnosed with dementia and 49.0% of them had behavioural
symptoms. Residents with dementia received more psycho-
tropic medication than residents without dementia (70.8%
vs. 55.0%; p<0.001). The most commonly prescribed med-
ications were antipsychotics (demented 44.8% vs. non-de-
mented 17.4%; p<0.001) and antidepressants (demented
29.6% vs. non-demented 26.7%; p<0.001). Antipsychotics
were mainly prescribed for residents with dementia and be-
havioural disturbances. The longitudinal analysis revealed
that most residents with dementia (69.5%) took anti-
psychotics continuously from entry to the final assessment
and the same was true for antidepressants (66.1%). The
use of antipsychotics at baseline in residents with dementia
predicted (p<0.001) the use of antipsychotics during
follow-up.
CONCLUSIONS: The long term use of antipsychotics in
nursing homes may need to be reconsidered in view of
novel treatment recommendations, suggesting that the pre-
scription of antipsychotics for patients with dementia
should be a second line treatment, restricted to symptoms
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BPSD: Behavioural and psychological symptoms of dementia
of psychosis or severe aggression, and prescribed for the
shortest duration possible.
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Introduction
Mental illness is common in nursing homes. Studies have
suggested that 50–70% of the residents suffer from demen-
tia [1] and more than 40% suffer from depressive disorders,
which often remain undiagnosed [2]. Common co-morbid-
ities of dementia are behavioural and psychological symp-
toms (BPSD) which are observed in almost 90% of nurs-
ing home residents during the progression of disease [3,
4]. They include aggressive and inappropriate behaviours,
wandering, agitation, anxiety, depressive mood, delusions
and hallucinations [5]. They are difficult to treat and are
a common reason for the high prescription rate of psycho-
tropic medication in nursing home residents with dementia
[6–8].
In studies across Europe, most residents (50–80%) of nurs-
ing and other care homes, particularly those with dementia,
take at least one psychotropic medication, mainly anti-
psychotics [9–13]. A cross-national study found that anti-
psychotics were more commonly prescribed in Swiss nurs-
ing homes (35.9%) compared to Canadian nursing homes
(32.9%) [8] and this trend has been confirmed in another
study showing higher prescription rates in Switzerland than
in Northern America or China [14]. The reasons for the dif-
ferences are not entirely understood, but they may be in
part related to different treatment standards or to different
access to treatment. It has been suggested that the prescrip-
tion of antipsychotics in nursing homes can be reduced
by practice recommendations [15], by specialised pharma-
ceutical support [16] or with regular reviews or educational
interventions [17].
There is converging evidence that antipsychotic use can be
associated with serious risks in patients with dementia. An-
tipsychotics seem to contribute to a more rapid progres-
sion of dementia [18], to higher rates of cerebrovascular
events [19, 20] and to increased mortality [21, 22]. Further
side effects of antipsychotics include sedation and dizzi-
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ness, which may lead to falls and fractures [23, 24]. Des-
pite these risks, antipsychotics are sometimes unavoidable
when non-pharmacological interventions have not been ef-
fective [25]. In such difficult clinical situations, potential
side effects of antipsychotics need to be carefully weighed
against potential benefits [26]. A systematic review sugges-
ted that there is no evidence for the long term use of an-
tipsychotics in the management of BPSD [27] and recent
clinical guidance suggests that antipsychotics should not be
the first line treatment for BPSD and, if unavoidable, the
duration of treatment should be kept to the lowest effective
dose and for the shortest duration possible [15, 28].
Here, we studied psychotropic medication use in a large
sample of Swiss nursing home residents at baseline and
during follow-up. We compared the prescription of differ-
ent psychotropic medication (antipsychotics, antidepress-
ants, anxiolytics and hypnotics) in residents without and
with dementia and hypothesised that psychotropic medic-
ation use is highest in residents with dementia, especially
for those with BPSD. Furthermore, we anticipated that the
prescription of antipsychotics is still rather continuous (i.e.




The nursing homes in the Swiss cantons of Aargau, Basel-
City and Solothurn (representing 13.5% of the Swiss popu-
lation) use the Resident Assessment Instrument Minimum
Data Set (RAI-MDS) for quality control and to assess func-
tional status or care needs [29]. Assessments are done by
trained nursing home staff. Residents are assessed at entry
and regularly at least every six months during follow-up.
Of 160 nursing homes invited to contribute their RAI-MDS
data, 90 homes agreed to provide their data for our re-
search, under the condition that the data was transferred an-
onymously and that no reference was made to a specific
nursing home or resident. The majority of nursing homes
contributing their data are run and owned by the com-
munity and are non-profit organisations. They offer care
for approximately 50 to 80 residents. The company (Q-
Sys AG: http://www.qsys.ch) pooling the RAI-MDS data
in Switzerland offered to be the intermediary organisation
between the nursing homes and the research team to guar-
antee anonymity. As the data were acquired for quality con-
trol and were anonymised, the ethical review board felt
that no ethical permission was needed in order to analyse
them. The original sample included 21821 residents who
lived in nursing homes during the time period from 1997 to
2007. The analysis of another study focussing on delirium
in nursing homes was also done within the sample [30]. For
the current study, only residents with a complete baseline
assessment during this ten year period were included for
the cross-sectional analysis (n = 18853) and those with
at least one follow-up assessment were included for the
follow-up analysis (n = 12101). The flow chart of the study
is summarised in figure 1.
Measurements
The data of the Swiss version of RAI-MDS, Version 2.0
1996 [29, 31] was prospectively collected by Q-Sys AG
and was provided to us for retrospective analysis. RAI-
MDS was developed by the US Institute of Medicine in
1986 for quality control. It has become the most widely
used instrument to assess the functional status and care
needs in nursing homes in Europe and Northern America.
It includes more than 300 individual items and 18 major
problem areas associated with nursing home residents, such
as medication group, delirium, communication, falls,
psychosocial well-being and cognitive loss. Information is
collected by observations of nursing home staff and inter-
views with residents, relatives or doctors in charge of the
residents. The RAI-MDS is also regularly used for research
studies [32].
For this study the following variables were included:
gender (male, female), age (years), living alone pre-admis-
sion (no, yes). Dementia was recorded as present or ab-
sent in the medical diagnosis section of RAI-MDS with no
further aetiological differentiation. All medical diagnoses
were made by the physicians in charge of the resident fol-
lowing the usual International Classification of Diseases
(ICD-10) diagnostic criteria (http://www.who.int/whosis/
icd10). The item “affective disorders” included anxiety, de-
pression and bipolar disorders. Diagnosis was based on
ICD-10 and was recorded as either present or absent. Af-
Figure 1 shows the flow chart with the number of residents
assessed at entry and during follow-up.
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fective disorders were considered to be present if at least
one affective disorder was present. The item “behavioural
disturbances” was assessed according to the observations
of the trained nurses in charge of the resident and included
the frequency of wandering, verbal and physical aggres-
sion, socially disruptive behaviours and resistance to care.
Behavioural disturbances were considered to be either
present or absent, if at least one of the five items was
present.
The use of antipsychotics, antidepressants, anxiolytics and
hypnotics were recorded as psychotropic medication in the
medication section of RAI-MDS. All medication groups
were categorised as present or absent but no recording
was made about the name or dosage of a specific medic-
ation. Continuous users were residents who had taken an-
tipsychotics or antidepressants at entry and throughout all
follow-up assessments. Intermittent users had the psycho-
tropic medication at entry with interruptions during follow-
up.
Statistical analyses
Data were analysed with the Statistical Package for Social
Sciences (Version 17.0). Categorical data were analysed
with Pearson chi-square tests and independent sample t-
tests were used for numerical variables. All p-values were
two tailed and the minimal significance level was set at p
≤0.001 to account for the large sample size and for mul-
tiple testing. A log-linear analysis was used to assess pre-
dictions of categorical variables (e.g. whether dementia and
antipsychotic use at entry predict the use of antipsychotics
at follow-up). It is an extension of the chi-square test and
allows analysis of complex contingency tables with more
than two categorical variables of interest.
Results
Demographic characteristics at entry
Demographic and clinical characteristics of the nursing
home residents at entry are summarised in table 1. Most
residents were females. Residents with dementia (40.2%)
were older and were less often living independently prior
to the nursing home admission. Behavioural disturbances
were more common in residents with dementia, unlike af-
fective disorders which were more commonly reported in
residents without dementia.
Psychotropic medication use at entry
Most residents (61.3%) received psychotropic medication,
and 28.4% of all residents received antipsychotics. Psy-
chotropic medication use was highest in residents with de-
mentia compared to residents without dementia (table 2).
More than 70% of the residents with dementia took at
least one psychotropic medication when entering the nurs-
ing home. A total of 49% of the residents with dementia
(3718 out of 7580) had behavioural disturbances and most
of them (77.7%) were on psychotropic medication. The
most commonly prescribed medication in residents with
dementia and behavioural disturbances were antipsychotics
(57.0%) followed by antidepressants (28.5%) which were
taken either solely or in combination with other psycho-
tropic medication.
The majority of residents without dementia (55.0%) were
on psychotropic medication as well, however the most
commonly prescribed medications were antidepressants
and not antipsychotics. This is well in line with the obser-
vation that affective disorders are also more common in
residents without dementia (see for comparison table 1).
Psychotropic medication use during follow-up
There were 12’101 residents eligible for the follow-up ana-
lysis (5287 with dementia and 6814 without dementia).
They had 3.1 (SD 0.9) follow-up assessments on average
and the average follow-up period was 12 months. In the
follow-up sample, there was no difference found with re-
Figure 2A shows the relative number of residents with dementia on
antipsychotics and with behavioural disturbances at entry and
during follow-up.
Table 1: Residents’ characteristics.
Residents with dementia Residents without dementia Odds Ratio (95% CI) p-value
Number 7580 11273 – –
Females 5134 (67.7) 7662 (68.0) 1.01 (0.98–1.05) = 0.733
Age [mean; ± SD] 84.0 ± 7.8 82.9 ± 9.2 – <0.001*
Living alone before admission 2870 (37.9) 5122 (45.4) 1.20 (1.15–1.24) <0.001
Behavioural disturbances (only) 2874 (37.9) 1443 (12.8) 5.14 (4.76–5.54) <0.001
Affective disorders (only) 923 (12.2) 1804 (16.0) 1.32 (1.20–1.44) <0.001
Depression 854 (11.3) 1693 (15.0) 1.29 (1.18–1.41) <0.001
Anxiety disorders 124 (1.6) 221 (2.0) 1.11 (1.02–1.20) = 0.006
Behavioural disturbances and affective disorders 844 (11.1) 478 (4.2) 3.45 (3.01–3.95) <0.001
Numbers expressed as n (%) unless otherwise indicated
* t (18851) = 7.79
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gards to age (p = 0.092), gender (p = 0.772) and other
socio-demographic variables (p = 0.035) when residents
with dementia were compared with those without demen-
Figure 2B shows the relative number of residents without dementia
on antipsychotics and with behavioural disturbances at entry and
during follow-up.
Figure 3A shows the relative number of residents with dementia on
antidepressants and with affective disorders at entry and during
follow-up.
tia. The number of residents decreased during follow-up:
8002 residents had an assessment 6 months after entry;
3627 were assessed 12 months after entry and 824 had an
assessment 18 months after entering a nursing home. Dur-
ing the follow-up period, 5.1% (967) of the residents were
newly diagnosed with dementia.
Antipsychotics and behavioural symptoms at entry and
during follow-up
Nearly half (49.6%) of the residents with dementia eligible
for follow-up had behavioural disturbances and 44.9% of
them received treatment with an antipsychotic at their entry
assessment. The prescription of antipsychotics during
follow-up was continuous in the majority (69.5%) of res-
idents with dementia. Furthermore, results of the log-linear
analysis showed that prescription of antipsychotics at entry
predicted (p <0.001) the prescription of antipsychotics at
the final assessment (95% CI: 2.65–3.03). A similar predic-
tion was found for behavioural disturbances at entry. They
also predicted (p <0.001) the prescription of antipsychot-
ics after 6 months (95% CI: 2.02–2.52), after 12 months
Figure 3B shows the relative number of residents without dementia
on antidepressants and with affective disorders at entry and during
follow-up.
Table 2: Psychotropic medication use at the entry assessment.
Residents with dementia Residents without dementia Odds Ratio (95% CI) p-value
Number 7580 11273 – –
Any psychotropic medication 5365 (70.8) 6203 (55.0) 1.98 (1.86–2.11) <0.001
Any antipsychotics 3397 (44.8) 1958 (17.4) 3.86 (3.62–4.13) <0.001
Any antidepressants 2243 (29.6) 3005 (26.7) 1.16 (1.08–1.23) <0.001
Use of psychotropic medication
Antipsychotics only 1639 (21.6) 803 (7.1) 3.60 (3.29–3.94) <0.001
Antidepressants only 799 (10.5) 1245 (11.0) 0.95 (0.86–1.04) = 0.276
Hypnotics only 523 (6.9) 1482 (13.1) 1.91 (1.73–2.09) <0.001
Anxiolytics only 174 (2.3) 350 (3.1) 1.14 (0.94–1.37) = 0.001
Antipsychotics and
antidepressants
653 (8.6) 389 (3.5) 2.64 (2.32–3.00) <0.001
Antipsychotics and
hypnotics
482 (6.4) 296 (2.6) 2.52 (2.17–2.92) <0.001
Antipsychotics and
anxiolytics
190 (2.5) 126 (1.1) 2.28 (1.81–2.85) <0.001
Antipsychotics and 2
others
381 (5.0) 277 (2.5) 3.97 (2.61–6.03) <0.001
All 4 classes 52 (0.7) 67 (0.6) 1.16 (0.80–1.66) = 0.436
Numbers expressed as n (%) unless otherwise indicated
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(95% CI: 2.16–2.81) and in the final assessment (95% CI:
1.89–2.37).
During the follow-up period, several residents with demen-
tia started treatment with antipsychotics (fig. 2A): 10.7%
started treatment within the first follow-up period (0 to 6
months); 6.1% started treatment in the second follow-up in-
terval (6 to 12 months) and 5.7% started treatment in the
third follow-up interval (12 to 18 months). In residents with
dementia, the prevalence of behavioural disturbances in-
creased during the first 12 months follow-up. However, the
percentage of residents with dementia taking antipsychot-
ics decreased after 12 months.
Antipsychotics were less commonly prescribed to residents
without dementia (18.7% of the 6814 eligible for follow-
up), and behavioural disturbances were also less common
(18.1%) than in residents with dementia (see fig. 2A and
2B). The majority of the residents without dementia (60%)
used antipsychotics continuously from the first to the final
assessment. However, the continuous prescription rate was
lower compared to the rate of residents with dementia (95%
CI: 1.32–1.75, p <0.001).
Antidepressants and depressive features at entry and
during follow-up
Of the residents with dementia eligible for follow-up,
24.2% had affective disorders and 30.9% received anti-
depressants at their entry assessment. Antidepressant use
at entry was also common in residents without dementia
(29.2%). They were prescribed continuously for residents
with dementia (66.1%) and for residents without dementia
(67.8%) with no significant group differences (95% CI:
0.98–1.07; p = 0.302). The two groups were also not dif-
ferent with regards to the prevalence of affective disorders
or the prescription of antidepressants during follow-up (see
fig. 3A and 3B). In both groups, the percentages of antide-
pressant users increased during follow-up and the percent-
ages of residents with affective disorders remained lower
than the percentages of antidepressant users.
Discussion
The current findings confirm that psychotropic medication
is commonly used in Swiss nursing homes, in the cantons
of Aargau, Basel-City and Solothurn. More than two thirds
of the residents with dementia were on psychotropic med-
ication, mainly antipsychotics, which were predominantly
prescribed for residents with behavioural disturbances. The
prescription of antipsychotics was rather continuous and
their use at entry predicted their use during follow-up. This
is in contrast with recent treatment recommendations sug-
gesting that the use of antipsychotics should be restricted to
clear target symptoms (i.e. severe aggression or psychosis)
and prescribed for shortest duration possible [15, 28].
As in previous studies, most residents received psycho-
tropic medication [33, 34]. Overall the use of psychotropic
medication is comparable with the rates found in other
European studies (50% to 80%) [9–12]. The rate in the cur-
rent study was slightly lower than in a previous study in
four French-speaking Swiss cantons, where 78% of the res-
idents were taking psychotropic medication [8]. The res-
idents in this previous study were, however, slightly older
and the prevalence of dementia tended to be higher and this
may explain part of the differences. The most commonly
used drugs in the French-speaking cantons were hypnotics
and anxiolytics, whereas in our study the most commonly
used drugs were antipsychotics. These differences may be
related to different approaches in the diagnosis and man-
agement of nursing home residents.
A total of 28% of all nursing home residents in the current
study were taking antipsychotics and this compares well
with the rates found in previous studies (22 to 34%) [14,
33, 35]. Behavioural symptoms and dementia were the
main predictors of antipsychotic prescription in nursing
home residents in previous research [36–38] and this was
likely the case in our sample too. The rather continuous
prescription of antipsychotics found here and in other stud-
ies [39] is not in agreement with treatment recommenda-
tions, which suggest that BPSD are rather transient phe-
nomena and that the need for continuing treatment needs to
be reviewed regularly every 3–6 months [28, 40–42].
This study included the RAI data from 1997 to 2007 and
it is therefore likely that the warnings about the potential
side effects of antipsychotics in patients with dementia,
which started in 2004, has not yet affected prescription
habits. Several studies have suggested that the use of an-
tipsychotics in patients with dementia can be associated
with a more rapid progression of dementia [18, 43], more
cerebrovascular events [19, 20] and higher mortality [21].
Furthermore, neuroleptic sensitivity is common in demen-
tia with Lewy bodies or Parkinson’s disease dementia [44,
45]. Risks can therefore outweigh potential benefits [46,
47] and antipsychotics should therefore not be used in gen-
eral as the first line treatment for BPSD. Common reas-
ons for prescribing them despite the risks mentioned are the
lack of trained nurses to apply non-pharmacological inter-
ventions. Such interventions include cognitive stimulation,
music therapy, snoezelen and other sensory stimulation for
example. They can be applied either in groups or on a one-
to-one basis [48]. Non-pharmacological interventions and
pharmacological alternatives to antipsychotics (e.g. antide-
pressants, cholinesterase inhibitors, memantine and antie-
pileptics) should be considered for residents with dementia,
before prescribing antipsychotics [49].
The number of residents treated with antidepressants was
higher than the prevalence of affective disorders. This in-
dicates possible under-diagnosis of affective disorders or
that depressive symptoms in the early phase of dementia
were treated but not explicitly diagnosed. Other studies
have found that under-diagnosis of depression in nursing
homes is common, especially in residents with dementia
[50, 51]. Although depressive features were not more com-
mon in residents with dementia compared to those without,
there were more demented residents treated with antide-
pressants during follow-up. This suggests that some resid-
ents with BPSD were treated with antidepressants, for the
management of aggression, depressive features or the treat-
ment of insomnia for example [52–54]. Switzerland cur-
rently has no national guidelines to define standards of care
for people with dementia. There are however local initi-
atives, in the canton of Fribourg for example, which have
shown that medication use in nursing homes can be re-
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duced by practice recommendations [15] or by specialised
pharmaceutical support [16].
In parallel to the strengths of the study, such as the sample
size or the use of an internationally used RAI-MDS meth-
odology, there are several limitations which need to be
considered when interpreting the findings. Firstly, RAI-
MDS was primarily developed for quality control. It is
a nurse led instrument and the medical information (e.g.
about medication) included in RAI-MDS is less detailed
than one would wish for research purposes. Details about
substance and dosage of medication are not recorded and
this limits the interpretation of our findings to substance
classes. The number of RAI-MDS assessments during
follow-up was variable and no clear final assessment was
done, when patients died for example. It was therefore
not possible to consider death as an outcome variable.
Anonymity was an important condition for the nursing
homes providing their data to our research. This condition
possibly increased the number of nursing homes willing
to contribute their data for research, however it restricted
the possibility to analyse differences between the nursing
homes, which has been done in previous research [8]. As
in all epidemiological studies, the method used here is less
detailed than in interventional studies. However, these lim-
itations were considered when drawing conclusions.
Conclusions
Psychotropic medication is commonly prescribed in Swiss
nursing homes and the most commonly prescribed medic-
ations to residents with dementia were antipsychotics and
antidepressants. Furthermore, the prescription of anti-
psychotics at entry predicted their use in the final assess-
ment in most residents. Continuous prescription of anti-
psychotics for more than 6 months in residents with demen-
tia needs to be carefully reconsidered in view of potential
risks, which include neuroleptic sensitivity, death, cardi-
ovascular events or more rapid disease progression. Re-
cent treatment recommendations suggest that non-pharma-
cological interventions should be considered first for the
treatment of BPSD before antipsychotics are used. If anti-
psychotics are prescribed for residents with dementia, their
use should be restricted to treat psychosis or severe ag-
gression and treatment should be given in the lowest ef-
fective dose for the shortest duration possible. Finally it
is recommended to review the need for continued treat-
ment regularly, every 3 to 6 months. Future research is
needed to determine whether regular medication reviews
and staff training are effective strategies to reduce psycho-
tropic medication use.
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Figures (large format)
Figure 1 shows the flow chart with the number of residents assessed at entry and during follow-up.
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Figure 2A Figure 2A shows the relative number of residents with dementia on antipsychotics and with behavioural disturbances at entry and
during follow-up.
Figure 2B shows the relative number of residents without dementia on antipsychotics and with behavioural disturbances at entry and during
follow-up.
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Figure 3A shows the relative number of residents with dementia on antidepressants and with affective disorders at entry and during follow-up.
Figure
Figure 3B shows the relative number of residents without dementia on antidepressants and with affective disorders at entry and during follow-
up.
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